Skip to main content

CL-PTL-119: Double-Blind, Placebo Controlled Phase III Trial of Maintenance FANG (bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) for High Risk Stage III/IV Ovarian Cancer

Research Grant
Duke Scholars

Administered By

Duke Cancer Institute

Awarded By

Gradalis, Inc.

Start Date

August 1, 2015

End Date

September 30, 2023
 

Administered By

Duke Cancer Institute

Awarded By

Gradalis, Inc.

Start Date

August 1, 2015

End Date

September 30, 2023